Anthony Clarke,Richard Allistair Stewart,Andrew Gareth Willis
申请号：
GB20170001939
公开号：
GB2550241(B)
申请日:
2017.02.06
申请国别(地区):
英国
年份:
2018
代理人:
摘要：
Disclosed is a succinate salt of cytisine, cytisine hydrogen succinate, which is a nicotinic acetylcholine receptor agonist. It appears that cytosine hydrogen succinate has enhanced stability relative to cytisine free base, which is marketed as Tabex (RTM). The enhanced stability allows for both longer shelf-life and a wider range of, more conventional, excipients to be used. Also disclosed are solvates and hydrates of succinate salts of cytisine and mixtures comprising cytisine hydrogen succinate and pharmaceutically acceptable excipients; the resultant pharmaceutical composition may be formulated as a tablet or capsule. Preferably the excipient is lactose, corn starch or wheat starch; most preferably, the excipient is lactose. The pharmaceutical composition may be used in the treatment of nicotine addiction; most preferably providing a unit dose of cytisine succinate of 1 to 3 milligrams
